- Home
- GILD vs MELI Comparison
GILD vs MELI Comparison
Compare GILD & MELI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- MELI
- Stock Information
- Founded
- GILD 1987
- MELI 1999
- Country
- GILD United States
- MELI Uruguay
- Employees
- GILD N/A
- MELI N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- MELI Catalog/Specialty Distribution
- Sector
- GILD Health Care
- MELI Consumer Discretionary
- Exchange
- GILD Nasdaq
- MELI Nasdaq
- Market Cap
- GILD 129.9B
- MELI 131.0B
- IPO Year
- GILD 1992
- MELI 2007
- Fundamental
- Price
- GILD $110.08
- MELI $2,563.29
- Analyst Decision
- GILD Buy
- MELI Strong Buy
- Analyst Count
- GILD 25
- MELI 13
- Target Price
- GILD $109.00
- MELI $2,593.85
- AVG Volume (30 Days)
- GILD 8.8M
- MELI 396.5K
- Earning Date
- GILD 04-24-2025
- MELI 05-07-2025
- Dividend Yield
- GILD 2.87%
- MELI N/A
- EPS Growth
- GILD 1118.07
- MELI 82.40
- EPS
- GILD 4.73
- MELI 40.65
- Revenue
- GILD $28,735,000,000.00
- MELI $22,379,000,000.00
- Revenue This Year
- GILD $1.54
- MELI $28.82
- Revenue Next Year
- GILD $3.70
- MELI $23.62
- P/E Ratio
- GILD $23.27
- MELI $63.06
- Revenue Growth
- GILD 4.68
- MELI 37.68
- 52 Week Low
- GILD $62.07
- MELI $1,550.00
- 52 Week High
- GILD $119.96
- MELI $2,635.88
- Technical
- Relative Strength Index (RSI)
- GILD 58.78
- MELI 65.66
- Support Level
- GILD $107.23
- MELI $2,501.10
- Resistance Level
- GILD $109.55
- MELI $2,584.69
- Average True Range (ATR)
- GILD 2.90
- MELI 59.95
- MACD
- GILD 1.01
- MELI -12.93
- Stochastic Oscillator
- GILD 90.02
- MELI 62.25
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About MELI MercadoLibre Inc.
MercadoLibre runs the largest e-commerce marketplace in Latin America, with more than 218 million active users and 1 million active sellers across 18 countries stitching into its commerce network or fintech solutions when last reported. The company operates a host of complementary businesses to its core online shop, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago and Mercado Credito), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.